US Stock MarketDetailed Quotes
ABBV AbbVie
- 157.060
- -1.200-0.76%
Close May 24 16:00 ET
- 157.290
- +0.230+0.15%
Post 19:56 ET
277.35BMarket Cap46.74P/E (TTM)
158.780High156.360Low3.69MVolume158.360Open158.260Pre Close580.11MTurnover0.21%Turnover Ratio57.74P/E (Static)1.77BShares181.19652wk High34.64P/B276.74BFloat Cap125.84752wk Low5.99Dividend TTM1.76BShs Float181.196Historical High3.81%Div YieldTTM1.53%Amplitude20.362Historical Low157.137Avg Price1Lot Size
AbbVie Stock Forum
Sign in to post a comment
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
4
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
28
36
$Novo-Nordisk A/S(NVO.US$ & $Eli Lilly and Co(LLY.US$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
4
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
5
1
$AbbVie(ABBV.US$ to acquire $Landos Biopharma(LABP.US$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
11
Richard Gonzalez's recent sale, despite a lower share price, suggests satisfaction with a lower valuation. High insider ownership but no insider buying in the last year raises caution.
Nvidia $NVIDIA(NVDA.US$
Walmart $Walmart(WMT.US$
$Advanced Micro Devices(AMD.US$
Costco $Costco(COST.US$
Taiwan Semiconductor $Taiwan Semiconductor(TSM.US$
CrowdStrike $CrowdStrike(CRWD.US$
JPMorgan $JPMorgan(JPM.US$
Airbnb $Airbnb(ABNB.US$
Palantir $Palantir(PLTR.US$
Qualcomm $Qualcomm(QCOM.US$
Target $Target(TGT.US$
Bank of America $Bank of America(BAC.US$
Wells Fargo $Wells Fargo & Co(WFC.US$
Spotify $Spotify Technology(SPOT.US$
...
Walmart $Walmart(WMT.US$
$Advanced Micro Devices(AMD.US$
Costco $Costco(COST.US$
Taiwan Semiconductor $Taiwan Semiconductor(TSM.US$
CrowdStrike $CrowdStrike(CRWD.US$
JPMorgan $JPMorgan(JPM.US$
Airbnb $Airbnb(ABNB.US$
Palantir $Palantir(PLTR.US$
Qualcomm $Qualcomm(QCOM.US$
Target $Target(TGT.US$
Bank of America $Bank of America(BAC.US$
Wells Fargo $Wells Fargo & Co(WFC.US$
Spotify $Spotify Technology(SPOT.US$
...
13
3
$Ironwood Pharmaceuticals(IRWD.US$ shares sank almost 40% after the drugmaker said its global phase III trial of Apraglutide, a treatment for short bowel syndrome, missed two of its four secondary goals.
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...
That muddies the prospects for the company that's seeking to expand its product pipeline beyond Linzess.
Ironwood, which has been operating at a loss, sourced almost ll of its $117.6 million revenue in 2023 from its collaborati...
6
$Bristol-Myers Squibb(BMY.US$
The price action of BMY is finding support near the 47.50 price point. It appears to be forming a double bottom on the charts so far.
There is a bullish divergence on several of the popular oscillating indicators for the weekly candles. The major indicators for the daily candles, like RSI and MACD, are all officially in bullish territory.
Ultimately, the price would need to climb out of the trading ...
The price action of BMY is finding support near the 47.50 price point. It appears to be forming a double bottom on the charts so far.
There is a bullish divergence on several of the popular oscillating indicators for the weekly candles. The major indicators for the daily candles, like RSI and MACD, are all officially in bullish territory.
Ultimately, the price would need to climb out of the trading ...
10
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Xiaobie : how do you read TRIPLE?